Search

Your search keyword '"Rimini M"' showing total 268 results

Search Constraints

Start Over You searched for: Author "Rimini M" Remove constraint Author: "Rimini M"
268 results on '"Rimini M"'

Search Results

1. Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy

2. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

3. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib

4. Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma

5. 93P The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study

6. 88P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)

7. Worldwide Disparities in Recovery of Cardiac Testing 1 Year Into COVID-19

8. C63 PREVALENCE AND CLINICAL SIGNIFICANCE OF RIGHT VENTRICULAR PULMONARY ARTERIAL UNCOUPLING IN CARDIAC AMYLOIDOSIS

9. Incidence and risk factors of esophagogastric varices bleeding in cirrhotic patients with advanced hepatocellular carcinoma treated with lenvatinib

10. 67P Real-world data for atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

11. 65P Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population

15. 84P Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population

18. Impact of COVID-19 on the imaging diagnosis of cardiac disease in Europe

19. Prevalence of interstitial pneumonia suggestive of COVID-19 at 18F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study

20. SO-3 Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma

21. PD-5 IDH1 in intrahepatic cholangiocarcinoma: A comparative genomic analysis and clinical impact

22. SO-14 Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study

23. P-126 Clustering analysis identified three IDH1-mutated intrahepatic cholangiocarcinoma's clusters with prognostic significance

24. Correction to: Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis (Targeted Oncology, (2021), 16, 3, (401-410), 10.1007/s11523-021-00797-3)

25. Impact of COVID-19 on the imaging diagnosis of cardiac disease in Europe

26. 952P Prognostic implication of serum alpha-fetoprotein in patients with unresectable hepatocellular carcinoma treated with regorafenib

29. Impact of COVID-19 Pandemic on Cardiovascular Testing in Asia

30. Prevalence of interstitial pneumonia suggestive of COVID-19 at 18F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study

33. Could inflammatory indices and metabolic syndrome predict the risk of cancer development? Analysis from the bagnacavallo population study

39. Poster display IV experimental and instrumentation

40. Posters display III clinical outcome and PET

41. 292P Extended molecular profiling (EMP) and access to targeted treatment (TT) in advanced biliary tract cancer (BTC): Results from the Italian cholangiocarcinoma dataset (ANITA).

42. 1474P Immune-inflammatory indexes and BMI as predictors of outcome and treatment response in advanced gastric cancer receiving ramucirumab-containing second-line

43. External Validation of Surrogate Indices of Fatty Liver in the General Population: The Bagnacavallo Study

45. Posters display III clinical outcome and PET

46. The prognostic nutritional index (PNI) is an independent predictor of survival in advanced biliary cancers (ABC) receiving first-line chemotherapy (1L)

47. A user-friendly nomogram to predict relapse-free survival (RFS) in western patients with resected gastric cancer (GC)

48. Immune-inflammatory and clinicopathologic prognostic factors in a Western cohort of resected gastric cancers (GCs)

49. Poster display IV experimental and instrumentation

Catalog

Books, media, physical & digital resources